Effect of β2-Adrenergic Receptor Polymorphism in Asthma Control of Patients Receiving Combination Treatment
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Purpose: Combination treatment of inhaled corticosteroid (ICS) plus long-acting β2-agonist (LABA) is widely used as a maintenance regimen for the management of asthma. This study evaluated the effect of the β2-adrenergic receptor (ADRB2) polymorphism on lung function and asthma control with regular use of combination treatment of an inhaled ICS plus LABA. Materials and Methods: 43 Korean asthmatics who were symptomatic despite regular ICS use for at least 3 months were enrolled. For a 2-week run-in period, they received ICS (budesonide 800 μg/day) plus terbutaline (5 μg prn). as needed. During the 24-week active treatment period, they received budesonide 160 μg and formoterol 4.5 μg b.i.d. as maintenance and rescue medication. Pulmonary function and quality of life scores were monitored every 8 weeks; morning/evening peak expiratory flow meter (PEFR) was recorded daily. Patients were genotyped for ADRB2 Arg16Gly using single base extension methodology. Results: During the run-in period, there were no significant between-group differences in lung function; after 8 weeks of active treatment, Arg/Arg patients had significantly higher forced expiratory volume in 1 secord (FEV1) and maximal mid-expiratory flow (MMEF) (p = 0.023 and p = 0.021, respectively), and better asthma control and quality of life after 24 weeks (p = 0.016 and p = 0.028, respectively). During treatment, there was a greater improvement in morning/evening PEFR in Arg/Arg patients. Conclusion: Asthmatic patients with the Arg/Arg genotype at codon 16 of ADRB2 achieve better asthma control with long-term regular use of combined budesonide and formoterol treatment, suggesting that the ADRB2 genotype may dictate choice of treatment strategy.
Abstract
Purpose: Combination treatment of inhaled corticosteroid (ICS) plus long-acting β2-agonist (LABA) is widely used as a maintenance regimen for the management of asthma. This study evaluated the effect of the β2-adrenergic receptor (ADRB2) polymorphism on lung function and asthma control with regular use of combination treatment of an inhaled ICS plus LABA. Materials and Methods: 43 Korean asthmatics who were symptomatic despite regular ICS use for at least 3 months were enrolled. For a 2-week run-in period, they received ICS (budesonide 800 μg/day) plus terbutaline (5 μg prn). as needed. During the 24-week active treatment period, they received budesonide 160 μg and formoterol 4.5 μg b.i.d. as maintenance and rescue medication. Pulmonary function and quality of life scores were monitored every 8 weeks; morning/evening peak expiratory flow meter (PEFR) was recorded daily. Patients were genotyped for ADRB2 Arg16Gly using single base extension methodology. Results: During the run-in period, there were no significant between-group differences in lung function; after 8 weeks of active treatment, Arg/Arg patients had significantly higher forced expiratory volume in 1 secord (FEV1) and maximal mid-expiratory flow (MMEF) (p = 0.023 and p = 0.021, respectively), and better asthma control and quality of life after 24 weeks (p = 0.016 and p = 0.028, respectively). During treatment, there was a greater improvement in morning/evening PEFR in Arg/Arg patients. Conclusion: Asthmatic patients with the Arg/Arg genotype at codon 16 of ADRB2 achieve better asthma control with long-term regular use of combined budesonide and formoterol treatment, suggesting that the ADRB2 genotype may dictate choice of treatment strategy.
참고문헌 (27)
- O’Byrne PM, "Budesonide", formoterol combination therapy as both maintenance and reliever medication in asthma, 2005, pp.171, 129~136
- Pauwels RA, "Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group", N Engl J Med, 337, pp.1405~1411 (1997)
- "Global initiative for asthma (gina) global strategy for asthma managemetn and prevention: National Instritutes of Health, National Heart" (2006), Lung and Blood Institute
- Israel E, "The effect of polymorphisms of the beta(2)- adrenergic receptor on the response to regular use of albuterol in asthma", Am J Respir Crit Care Med, 162, pp.75~80 (2000)
- Israel E, "Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial", Lancet, 364, pp.1505~1512 (2004)
- Wechsler ME, "beta-Adrenergic receptor polymorphisms and response to salmeterol", Am J Respir Crit Care Med, 173, pp.519~526 (2006)
- Palmer CN, "Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol", Thorax, 61, pp.940~944 (2006)
- Lee DK, "The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol", Br J Clin Pharmacol, 57, pp.68~75 (2004)
- Cho SH, "Association between bronchodilating response to short-acting betaagonist and non-synonymous single-nucleotide polymorphisms of beta-adrenoceptor gene", Clin Exp Allergy, 35, pp.1162~1167
- Taylor DR, "Bronchodilator response in relation to beta2-adrenoceptor haplotype in patients with asthma", Am J Respir Crit Care Med, 172, pp.700~703 (2005)
- Hancox RJ, "Polymorphism of the beta2- adrenoceptor and the response to long-term beta2-agonist therapy in asthma", Eur Respir J, 11, pp.589~593 (1998)
- Taylor DR, "Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism", Thorax, 55, pp.762~767 (2000)
- Bleecker ER, "Salmeterol response is not affected by beta2- adrenergic receptor genotype in subjects with persistent asthma", J Allergy Clin Immunol, 118, pp.809~816 (2006)
- Bleecker ER, "Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies", Lancet, 370, pp.2118~2125 (2007)
- Choudhry S, "Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma", Am J Respir Crit Care Med, 171, pp.563~570 (2005)
- Rho HJ, "Factors influencing quality of life of asthmatic patients in Korea", J Asthma Allergy Clin Immunol, 20, pp.209~221 (2000)
- Liggett SB, "Polymorphisms of the beta2-adrenergic receptor and asthma", Am J Respir Crit Care Med, 156, pp.S156~S162 (1997)
- Holloway JW, "Association of beta2-adrenergic receptor polymorphisms with severe asthma", Clin Exp Allergy, 30, pp.1097~1103 (2000)
- Contopoulos-Ioannidis DG, "Meta-analysis of the association of beta2-adrenergic receptor polymorphisms with asthma phenotypes", J Allergy Clin Immunol, 115, pp.963~972 (2005)
- Reihsaus E, "Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects", Am J Respir Cell Mol Biol, 8, pp.334~339 (1993)
- Martinez FD, "Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing", J Clin Invest, 100, pp.3184~3188 (1997)
- Drysdale CM, "Complex promoter and coding region beta 2- adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness", Proc Natl Acad Sci U S A, 통권 : 97, pp.10483~10488 (2000)
- Munakata M, "Molecular-based haplotype analysis of the beta 2-adrenergic receptor gene (ADRB2) in Japanese asthmatic and non-asthmatic subjects", Allergol Int, 55, pp.191~198 (2006)
- Green SA, "Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonistpromoted regulatory properties", Biochemistry, 33, pp.9414~9419 (1994)
- Green SA, "Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells", Am J Respir Cell Mol Biol, 13, pp.25~33 (1995)
- Green SA, "The Ile164 beta(2)- adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s)", Eur J Pharmacol, 421, pp.141~147 (2001)
- Green SA, "A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor", J Biol Chem, 268, pp.23116~23121 (1993)